Canada markets close in 5 hours 6 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
12.99+0.02 (+0.19%)
As of 10:53AM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • D
    I trust the R and D , and advanced research capabilities. It is still the 2nd largest western economy after US.
  • g
    I worked for AZ for 20 plus years in many countries. AZ always had a strong international presence and were probably the first to develop the Chinese Market.
    Takeda are the opposite.
    Belatedly into China
    and their international launches poorly managed.
    Why have I invested?
    Surely they will improve and launch their new products effectively.
    The dengue vaccine will test their marketing/sales ability.

    Still not approved in Europe and USA.
    TAKEDA share price continues to fall but I will
    probably increase my holding.
  • D
    The exports and foreign income will surge with low japanese yen.
  • b
    $TAC presented at ERS2020 for $ARWR AAT. Must be the start of PhaseIII.
  • g
    Is there something holding down TAK share price?
    First dengue vaccine approval, YEN lower again, 142 to usd, and shares down again.
    Probably down to lack of confidence globally.
    Any thoughts??
  • g
    I would value some help. Recently bought a modest amount of Takeda shares. Can someone
    please advise me of the NET Dividend for UK shareholders ie after any withholding tax. Thank you.
    es etc
  • g
    Sorry. USD not AUD.
  • g
    More gloom in Takeda share price, about to test the 14 AUD resistance level.
    Indonesia aside, the Dengue vaccine approval is interminable.
    Very little good news here.
  • b
    It's been a long time, but finally TAK's dengue vaccine is approved in a country. Many more nations to follow.

    @@@OSAKA, Japan, and CAMBRIDGE, Massachusetts, August 22, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. The use of QDENGA should be in accordance with official recommendations. QDENGA is the only dengue vaccine approved in Indonesia for use in individuals regardless of previous dengue exposure and without the need for pre-vaccination testing.1
  • 3
    back in
  • g
    Indonesian dengue vaccine approval is a a very small step for Takeda. The vaccine market will be hard to succeed in however Takeda's vaccine has clear advantages and fills a vacuum.
    The 1.6 US Blion peak ses forecast is very achievable and 2 billion plus is quite realistic.
    Takeda look a cautious buy following the Shire shockwaves.
  • g
    Very reasonable forecast. Approval (1st) of Dengue vaccine in Indonesia is a step forward.
    Other Regulators should approve very soon. Qdenga should exceed 1.6 billion usd peak sales.
    Takeda should push Regulators to approve this product.
  • j
    sweet, graham, sell your shares because it is going to be lower
  • g
    Takeda continues to disappoint. First Dengue fever approval,
    Yen continues its decline hitting 140 to usd and debt reduced.
    They have had manufacturing issues but, that aside, the shares APPEAR TO BE UNDERVALUED. A modest dividend increase would be a positive sign, indicating confidence. For now FRUSTRATED!
  • P
    No information about dividend payment history
    under historical information ...?
  • a
    Anyone get their dividend yet?
  • j
    profit drops a lot
  • T
    $ARWR conversation
    from bikerieder on twitter:

    when pressed by madhu Kumar on talks with the fda concerning streamlining the aat trial, here was ca's response: Ca on aat study: “so Javier is probably dying to answer that question…but I can’t let him…here’s the deal. We were so excited about those data for a lot of reasons. I believe that it suggested this drug is doing what we wanted to do. In fact, doing a bit faster than we expected. And so we are going with those data and probably some additional data to the fda to talk about changing endpoints and changing size and maybe changing the duration of the study. Until we have those discussions, it’s probably not appropriate for us to speculate on the specifics of what those changes could be. I don’t want to get out in front of this conversation. We’ve had a very good collaborative relationship with the fda as it relates to this program, we expect this to continue to be collaborative, and I just don’t want to jeopardize that. I want to have the discussion, an open discussion with them and then come back to you and tell you what we have decided together.”

    then Mariano: "BIG STEP, $ARWR ARO-AAT showing polymer reduction both in liver cells and in serum. $TAK must have been convinced Arrowhead Pharma’s drug for A1AD will be a winner! Equates to same scenario as with $JNJ J&J purchase of ARO-HBV asset, too."

    color on the ongoing dialogue could come sooner than we think....just another short-term catalyst for arwr longs.